Mutual of America Capital Management LLC Has $5.34 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Mutual of America Capital Management LLC lessened its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 0.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 119,857 shares of the company’s stock after selling 311 shares during the period. Mutual of America Capital Management LLC owned approximately 0.26% of Omnicell worth $5,336,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Van ECK Associates Corp raised its position in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares in the last quarter. KBC Group NV increased its holdings in shares of Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares in the last quarter. CIBC Asset Management Inc acquired a new stake in shares of Omnicell during the fourth quarter worth approximately $201,000. Finally, Summit Global Investments acquired a new stake in shares of Omnicell during the third quarter worth approximately $221,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Performance

OMCL stock opened at $37.73 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The company has a 50 day moving average price of $42.26 and a 200 day moving average price of $43.79. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The stock has a market capitalization of $1.75 billion, a PE ratio of 139.75, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

Insiders Place Their Bets

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.64% of the company’s stock.

Analyst Ratings Changes

OMCL has been the subject of several recent analyst reports. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Wells Fargo & Company dropped their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Benchmark reaffirmed a “buy” rating and set a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $52.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.